Search
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigationalOriginally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.[A258298] … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: MEKINIST®2 MG TABLETAS RECUBIERTAS, MEKINIST 2 MG FILM KAPLI TABLET ,7 TABLETPectin
go.drugbank.com/drugs/DB11158ApprovedInvestigationalVet approved[L1961] The carboxylic group of the constituents of pectin can exist in the form of esters, free acids, ammonium, potassium or sodium salts or as acid amides. … Under the FDA regulation, pectin qualifies as a GRAS (generally recognized as safe) food substance. This status allows pectin to be used with no limitations.[L1960]
Mixtures: Diban Cap, Diban CapCategories: Compounds used in a research, industrial, or household settingAngiotensin-converting enzyme
go.drugbank.com/bio_entities/BE0000221TargetEnzymeHumansDipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation … Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the
Synonyms: Dipeptidyl carboxypeptidase IVildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[L32813] Vildagliptin is currently under investigation in the US. … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea
Mixtures: GALVUS® MET 50/500 COMPRIMIDOS RECUBIERTOS CON PELICULA, GALVUS® MET COMPRIMIDO RECUBIERTO CON PELICULA 50 MG/850 MGCategories: DPP-IV Inhibitors, Drugs Used in DiabetesDNA ligase 1
go.drugbank.com/bio_entities/BE0000199TargetHumansDNA ligase that seals nicks in double-stranded during DNA repair (PubMed:30395541). Also involved in DNA replication and DNA recombination
Synonyms: DNA ligase IDiffuse Large B-Cell Lymphoma, Not Otherwise Specified
go.drugbank.com/conditions/DBCOND0080506Drugs: Polatuzumab vedotinSynonyms: Malignant lymphoma, large B-cell, diffuse, no ICD-O subtype, Malignant lymphoma, large B-cell, diffuse, no International Classification of Diseases for Oncology subtypeAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.
Mixtures: Neo VagexDocetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigational[A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxelNeon
go.drugbank.com/drugs/DB11589ApprovedIt is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Neon is a chemical element with a chemical symbol Ne and atomic number 10. It is a noble gas that is colorless, odorless, inert and monatomic.
Mixtures: Lung Diffusion Test Mix No Ne Co, Co-NE-O2-N2 MixtureSynonyms: NeNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodySynonyms: Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4, *01 (90.1%)) (8.8.19) (1-126) -homo sapiens ighg1*03